315 related articles for article (PubMed ID: 23931277)
1. Updating the use of synthetic peptides as inhibitors of HIV-1 entry.
Gómara MJ; Haro I
Curr Med Chem; 2014 Apr; 21(10):1188-200. PubMed ID: 23931277
[TBL] [Abstract][Full Text] [Related]
2. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
3. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
4. An insight on the leading HIV entry inhibitors.
Veiga AS; Santos NC; Castanho MA
Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):67-73. PubMed ID: 18221135
[TBL] [Abstract][Full Text] [Related]
5. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
6. [The current progress in the development of HIV-1 fusion inhibitors].
Shi WG; Jia QY; Liu KL
Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
[TBL] [Abstract][Full Text] [Related]
7. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L; Gochin M; Liu K
Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
Yi HA; Fochtman BC; Rizzo RC; Jacobs A
Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
[TBL] [Abstract][Full Text] [Related]
9. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
10. Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.
Pu J; Wang Q; Xu W; Lu L; Jiang S
Viruses; 2019 Aug; 11(8):. PubMed ID: 31374953
[TBL] [Abstract][Full Text] [Related]
11. Evolved Proteins Inhibit Entry of Enfuvirtide-Resistant HIV-1.
Ikeda T; Tennyson RL; Walker SN; Harris RS; McNaughton BR
ACS Infect Dis; 2019 Apr; 5(4):634-640. PubMed ID: 30811933
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of viral entry.
Melby T; Westby M
Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
[TBL] [Abstract][Full Text] [Related]
13. Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML; Cammack N
J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
[TBL] [Abstract][Full Text] [Related]
14. Is there a future for antiviral fusion inhibitors?
Berkhout B; Eggink D; Sanders RW
Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966
[TBL] [Abstract][Full Text] [Related]
15. Development of HIV-1 fusion inhibitors targeting gp41.
Lu K; Asyifah MR; Shao F; Zhang D
Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
[TBL] [Abstract][Full Text] [Related]
16. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
17. gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure.
D'Arrigo R; Ciccozzi M; Gori C; Montieri S; Aquaro S; Bellagamba R; Boumis E; Di Perri G; Pizzi D; Antinori A; Rezza G; Perno CF
AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1296-302. PubMed ID: 17961119
[TBL] [Abstract][Full Text] [Related]
18. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins.
Steffen I; Pöhlmann S
Curr Pharm Des; 2010; 16(9):1143-58. PubMed ID: 20030613
[TBL] [Abstract][Full Text] [Related]
19. Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
Lu L; Yu F; Cai L; Debnath AK; Jiang S
Curr Top Med Chem; 2016; 16(10):1074-90. PubMed ID: 26324044
[TBL] [Abstract][Full Text] [Related]
20. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
Cooper DA; Lange JM
Lancet Infect Dis; 2004 Jul; 4(7):426-36. PubMed ID: 15219553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]